Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

NCT ID: NCT01345929

Last Updated: 2018-10-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 558 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-06-20
• Study Completion Date: 2013-09-04

Brief Summary

This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA 201 IV infusions (1500 mg q8h) versus levofloxacin IV infusions (750 mg qd) for the treatment of adults with a cUTI (including pyelonephritis).

Detailed Description

Approximately 500 subjects will be enrolled into this study and randomized 1:1 to receive CXA-201 or comparator (levofloxacin) resulting in 250 subjects per treatment arm. Subject participation will require a minimum commitment of 35 days and a maximum of 42 days. Subjects will be hospitalized for the administration of all doses of IV study therapy. A test of cure visit will occur at 7 days after the last dose of study drug and a late follow-up evaluation or contact will occur a minimum of 28 days and a maximum of 35 days after the last dose of study drug.

Conditions

Complicated Urinary Tract Infection; Pyelonephritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CXA-201 as treatment for cUTI

CXA-201 IV infusion (1500mg q8) for 7 days

Group Type: EXPERIMENTAL

CXA-201

Intervention Type: DRUG

CXA-201 IV infusion (1500mg q8) for 7 days

Levofloxacin as treatment for cUTI

Levofloxacin IV infusion (750mg qd) for 7 days

Group Type: ACTIVE_COMPARATOR

Levofloxacin

Intervention Type: DRUG

Levofloxacin IV infusion (750mg qd) for 7 days

Interventions

CXA-201

CXA-201 IV infusion (1500mg q8) for 7 days

Intervention Type: DRUG

Levofloxacin

Levofloxacin IV infusion (750mg qd) for 7 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Provide written informed consent prior to any study-related procedure not part of normal medical care (a legally acceptable representative may provide consent if the subject is unable to do so, provided this is approved by local country and institution specific guidelines).

2. Be males or females ≥ 18 years of age

3. If female, subject is non-lactating, and is either:

1. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or

2. Of childbearing potential and is practicing a barrier method of birth control (e.g., a diaphragm or contraceptive sponge) along with 1 of the following methods: oral or parenteral contraceptives (for 3 months prior to study drug administration), or a vasectomized partner. Or, subject is practicing abstinence from sexual intercourse. Subjects must be willing to practice these methods for the duration of the trial and for at least 35 days after last dose of study medication.

4. Males are required to practice reliable birth control methods (condom or other barrier device) during the conduct of the study and for at least 35 days after last dose of study medication.

5. Pyuria (white blood cell [WBC] count > 10/μL in unspun urine or ≥ 10 per high power field in spun urine).

6. Clinical signs and/or symptoms of cUTI, either of:

1. Pyelonephritis, as indicated by at least 2 of the following:

• Documented fever (oral temperature > 38°C) accompanied by patient symptoms of rigors, chills, or "warmth";
• Flank pain;
• Costovertebral angle tenderness or suprapubic tenderness on physical exam; or
• nausea or vomiting; OR

2. Complicated lower UTI, as indicated by at least 2 of the following:

• At least 2 of the following new or worsening symptoms of cUTI:

• Dysuria; urinary frequency or urinary urgency;
• Documented fever (oral temperature > 38°C) accompanied by patient symptoms of rigors, chills, or "warmth";
• Suprapubic pain or flank pain;
• Costovertebral angle tenderness or suprapubic tenderness on physical exam; or
• Nausea or vomiting; plus,
• At least 1 of the following complicating factors:

• Males with documented history of urinary retention;
• Indwelling urinary catheter that is scheduled to be removed during IV study therapy and before the EOT;
• Current obstructive uropathy that is scheduled to be medically or surgically relieved during IV study therapy and before the EOT; or
• Any functional or anatomical abnormality of the urogenital tract (including anatomic malformations or neurogenic bladder) with voiding disturbance resulting in at least 100 mL residual urine.

7. Have a pretreatment baseline urine culture specimen obtained within 24 hours before the start of administration of the first dose of study drug.

NOTE: Subjects may be enrolled in this study and start IV study drug therapy before the Investigator knows the results of the baseline urine culture.

8. Require IV antibacterial therapy for the treatment of the presumed cUTI.

Exclusion Criteria

1. Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam or quinilone antibacterial (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)

2. Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity [e.g., vancomycin, linezolid] are allowed.)

3. Receipt of any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before administration of the first dose of study drug.

4. Receipt of any dose of a potentially therapeutic antibacterial agent for the treatment of the current UTI within 48 hours before the study-qualifying pretreatment baseline urine is obtained (exceptions: subjects with an active cUTI who have received prior antibiotics may be enrolled provided a minimum of 48 hours have elapsed between the last dose of the prior antibiotic and the time of obtaining the baseline urine specimen. Subjects receiving current antibiotic prophylaxis for cUTI who present with signs and symptoms consistent with an active new cUTI may be enrolled provided all other eligibility criteria are met including obtaining a pre-treatment qualifying baseline urine culture).

5. Intractable urinary infection at baseline that the Investigator anticipates would require more than 7 days of study drug therapy.

6. Complete, permanent obstruction of the urinary tract.

7. Confirmed fungal urinary tract infection at time of randomization (with ≥ 103 fungal CFU/mL).

8. Permanent indwelling bladder catheter or urinary stent including nephrostomy.

9. Suspected or confirmed perinephric or intrarenal abscess.

10. Suspected or confirmed prostatitis.

11. Ileal loop or known vesico-ureteral reflux.

12. Severe impairment of renal function including an estimated CrCl < 30 mL/min, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine output over 24 hours).

13. Current urinary catheter that is not scheduled to be removed before the EOT (intermittent straight catheterization during the IV study drug administration period is acceptable).

14. Any condition or circumstance that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of study data.

15. Any rapidly progressing disease or immediately life-threatening illness including acute hepatic failure, respiratory failure, and septic shock.

16. Immunocompromising condition, including established AIDS, hematological malignancy, or bone marrow transplantation, or immunosuppressive therapy including cancer chemotherapy, medications for prevention of organ transplantation rejection, or the administration of corticosteroids equivalent to or greater than 40 mg of prednisone per day administered continuously for more than 14 days preceding randomization.

17. One or more of the following laboratory abnormalities in baseline specimens: aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase, or total bilirubin level greater than 3 times the upper limit of normal (ULN), absolute neutrophil count less than 500/μL, platelet count less than 40,000/μL, or hematocrit less than 20%.

18. Participation in any clinical study of an investigational product within 30 days prior to the proposed first day of study drug.

19. Previous participation in any study of CXA-101 or CXA-201.

20. Women who are pregnant or nursing.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Obiamiwe Umeh, M.D., MSc.

Role: STUDY_DIRECTOR

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Locations

San Diego, California, United States

Wheat Ridge, Colorado, United States

Hialeah, Florida, United States

Teaneck, New Jersey, United States

Charleston, South Carolina, United States

Belo Horizonte, Minas Gerais, Brazil

Porto Alegre, Rio Grande de Sul, Brazil

Joinville, Santa Catarina, Brazil

Campinas, São Paulo, Brazil

Sao Jose de Rio Preto, São Paulo, Brazil

Rio de Janeiro, , Brazil

São Paulo, , Brazil

Cali, Valle del Cauca Department, Colombia

Armenia, , Colombia

Barranquilla, , Colombia

Bogotá, , Colombia

Kohtla-Järve, , Estonia

Tallinn, , Estonia

Tartu, , Estonia

Tbilisi, , Georgia

Giessen, Hesse, Germany

Lübeck, Schleswig-Holstein, Germany

Miskolc, Borsod-Abauj Zemplen county, Hungary

Gyor, Budapest, Hungary

Szentes, Csongrád megye, Hungary

Sopron, Győr-Moson-Sopron, Hungary

Salgótarján, Nógrád megye, Hungary

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Zalaegerszeg, Zala County, Hungary

Budapest, , Hungary

Tatabánya, , Hungary

Kfar Saba, Sharon, Israel

Petah Tikva, Teah Tiqwa, Israel

Tel Litwinsky, Tel Aviv, Israel

Haifa, , Israel

Jerusalem, , Israel

Safed, , Israel

Daugavpils, , Latvia

Liepāja, , Latvia

Riga, , Latvia

Valmiera, , Latvia

Ventspills, , Latvia

Guadalajara, Jalisco, Mexico

Chihuahua City, , Mexico

San Luis Potosí City, , Mexico

Veracruz, , Mexico

Chisinau, , Moldova

Oradea, Bihor County, Romania

Bucharest, București, Romania

Timișoara, Timiș County, Romania

Brasov, , Romania

Bucharest, , Romania

Iași, , Romania

Sibiu, , Romania

Kemerovo, , Russia

Moscow, , Russia

Nizhny Novgorod, , Russia

Novosibirsk, , Russia

Penza, , Russia

Saint Petersburg, , Russia

Saratov, , Russia

Belgrade, , Serbia

Banská Bystrica, , Slovakia

Levice, , Slovakia

Martin, , Slovakia

Prešov, , Slovakia

Skalica, , Slovakia

Bloemfontein, Free State, South Africa

Pretoria, Gauteng, South Africa

Soweto, Gauteng, South Africa

Middleburg, Mpumalanga, South Africa

Bellville, Western Cape, South Africa

Nakorn Ratchasima, Changwat Nakhon Ratchasima, Thailand

Chiang Mai, , Thailand

Lopburi, , Thailand

Prachuap Khiri Khan, , Thailand

Countries

United States; Brazil; Colombia; Estonia; Georgia; Germany; Hungary; Israel; Latvia; Mexico; Moldova; Romania; Russia; Serbia; Slovakia; South Africa; Thailand

References

Popejoy MW, Long J, Huntington JA. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam. BMC Infect Dis. 2017 May 2;17(1):316. doi: 10.1186/s12879-017-2414-9.

Reference Type: DERIVED

PMID: 28464828 (View on PubMed)

Xiao Y, Tong ML, Liu LL, Lin LR, Chen MJ, Zhang HL, Zheng WH, Li SL, Lin HL, Lin ZF, Xing HQ, Niu JJ, Yang TC. Novel predictors of neurosyphilis among HIV-negative syphilis patients with neurological symptoms: an observational study. BMC Infect Dis. 2017 Apr 26;17(1):310. doi: 10.1186/s12879-017-2339-3.

Reference Type: DERIVED

PMID: 28446129 (View on PubMed)

Kullar R, Wagenlehner FM, Popejoy MW, Long J, Yu B, Goldstein EJ. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam. J Antimicrob Chemother. 2017 Mar 1;72(3):900-905. doi: 10.1093/jac/dkw486.

Reference Type: DERIVED

PMID: 27999024 (View on PubMed)

Armstrong ES, Mikulca JA, Cloutier DJ, Bliss CA, Steenbergen JN. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC Infect Dis. 2016 Nov 25;16(1):710. doi: 10.1186/s12879-016-2057-2.

Reference Type: DERIVED

PMID: 27887579 (View on PubMed)

Huntington JA, Sakoulas G, Umeh O, Cloutier DJ, Steenbergen JN, Bliss C, Goldstein EJ. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother. 2016 Jul;71(7):2014-21. doi: 10.1093/jac/dkw053. Epub 2016 Mar 18.

Reference Type: DERIVED

PMID: 26994090 (View on PubMed)

Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015 May 16;385(9981):1949-56. doi: 10.1016/S0140-6736(14)62220-0. Epub 2015 Apr 27.

Reference Type: DERIVED

PMID: 25931244 (View on PubMed)

Other Identifiers

CXA-cUTI-10-04

Identifier Type: OTHER

Identifier Source: secondary_id

CXA-cUTI-10-05

Identifier Type: OTHER

Identifier Source: secondary_id

7625A-005

Identifier Type: -

Identifier Source: org_study_id

NCT01345955

Identifier Type: -

Identifier Source: nct_alias